Skip to Content
Merck
  • CYB5R1 links epithelial-mesenchymal transition and poor prognosis in colorectal cancer.

CYB5R1 links epithelial-mesenchymal transition and poor prognosis in colorectal cancer.

Oncotarget (2016-04-28)
Christine Woischke, Cristina Blaj, Eva Marina Schmidt, Sebastian Lamprecht, Jutta Engel, Heiko Hermeking, Thomas Kirchner, David Horst
ABSTRACT

Colorectal cancers show significant tumor cell heterogeneity within the same core genetic background. Epithelial-mesenchymal transition (EMT) is an important functional aspect of this heterogeneity and hallmark of colorectal cancer progression. Here, we identify CYB5R1, an enzyme involved in oxidative stress protection and drug metabolism, as an indicator of EMT in colon cancer. We demonstrate high CYB5R1 expression in colorectal cancer cells undergoing EMT at the infiltrative tumor edge and reveal an extraordinarily strong association of CYB5R1 expression with two core EMT gene expression signatures in a large independent colon cancer data set from The Cancer Genome Atlas (TCGA). Furthermore, we demonstrate that CYB5R1 is required for an infiltrative tumor cell phenotype, and robustly linked with poor prognosis in colorectal cancer. Our findings have important implications for colon cancer cells undergoing EMT and may be exploited for diagnostic and therapeutic purposes.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-CYB5R1 antibody produced in rabbit, Ab1, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution